Firm details
This firm has not yet provided any supplementary information. Please contact us for firm profiling options.
Key statistics
- Ranked Practice Areas
- 15
- Awards Won
- 13
- Recognised Lawyers
- 22
- Male:Female Ratio of Recognised Lawyers
- 13:9
Rankings
within China
| Practice Area Subcategory | Index Rank | Ave. Tier | Table | ||
|---|---|---|---|---|---|
| Antitrust and competition | |||||
| General | 3 | 1.7 | View full ranking table | ||
| Banking and finance | |||||
| General | 10 | 4.0 | View full ranking table | ||
| Capital markets | |||||
| Debt | 2 | 2.0 | View full ranking table | ||
| Equity | 2 | 2.0 | View full ranking table | ||
| General | 5 | 2.0 | View full ranking table | ||
| Construction | |||||
| General | 7 | Notable | View full ranking table | ||
| Corporate and M&A | |||||
| General | 4 | 2.0 | View full ranking table | ||
| Dispute resolution | |||||
| Arbitration | 7 | 3.0 | View full ranking table | ||
| General | 12 | 3.3 | View full ranking table | ||
| Energy and natural resources | |||||
| General | 7 | 3.0 | View full ranking table | ||
| Healthcare and lifesciences | |||||
| General | 6 | 3.0 | View full ranking table | ||
| Insurance | |||||
| General | 6 | 2.3 | View full ranking table | ||
| Intellectual property | |||||
| Disputes | 13 | Notable | View full ranking table | ||
| General | 20 | 4.0 | View full ranking table | ||
| Investment funds | |||||
| General | 10 | 3.0 | View full ranking table | ||
| Private equity | |||||
| General | 15 | 3.7 | View full ranking table | ||
| Project development | |||||
| including energy and infrastructure | 5 | 2.0 | View full ranking table | ||
| Real estate | |||||
| General | 9 | 3.3 | View full ranking table | ||
| Restructuring and insolvency | |||||
| General | 4 | 2.0 | View full ranking table | ||
Deals/Case awards
Total win-to-nominations ratio
1:13
| Award | Ratio |
|---|---|
| Capital markets - Debt | |
| Sino Biopharmaceutical €750 million convertible bonds | 0:1 |
| Capital markets - Equity | |
| Bilibili secondary listing on HKEX | 0:1 |
| Financial Street Property IPO and listing in Hong Kong | 0:1 |
| Hepalink $532 million Hong Kong IPO | 0:1 |
| New Oriental secondary listing on HKEX | 0:2 |
| Nongfu Spring IPO and listing in Hong Kong | 0:1 |
| Yihai Kerry Arawana A-share IPO | 0:1 |
| Corporate and M&A | |
| ChemChina Group / Sinochem Group agricultural businesses consolidation | 0:1 |
| China Yangtze Power / Peruvian electricity company acquisition | 1:1 |
| FAW Xialli major assets restructuring and CRM core quality assets listing | 0:1 |
| Hyundai Heavy Industries / Doosan Infracore acquisition | 0:1 |
| Energy and natural resources | |
| ChemChina Group / Sinochem Group agricultural businesses consolidation | 0:1 |
Firm awards
Total win-to-nominations ratio
12:26
| Award | Ratio |
|---|---|
| APAC regional awards | |
| Insurance | 0:1 |
| National awards | |
| Antitrust and competition | 1:2 |
| Capital markets | 1:4 |
| Construction | 1:1 |
| Corporate and M&A | 1:1 |
| Dispute resolution | 1:2 |
| Education | 2:2 |
| Firm of the year | 1:2 |
| Healthcare and life sciences | 1:2 |
| Intellectual property - Copyright | 1:1 |
| Investment funds | 0:1 |
| Labour and employment | 0:1 |
| Real estate | 0:1 |
| Regulatory | 1:1 |
| Technology, media, telecoms | 0:1 |
| Transactions | 0:1 |
| White collar crime | 1:1 |
| Practice management | |
| Innovative firm of the year | 0:1 |
Recognised lawyers
All data gathered from 2021 datasets. Learn more.